Journal Article Epublish
PubMed: 42741445 DOI: 10.1002/hem3.70483
DDX41 mutations establish a separate entity in acute myeloid leukemia with distinct survival outcomes.
Hemasphere 10(9):e70483
Authors: Carolin Seeling, Maral Saadati, Daniela Späth, Michael Heuser, Felicitas Thol, Arnold Ganser, Elli Papaemmanuil, Lars Bullinger, Axel Benner, Hartmut Döhner, Konstanze Döhner
Affiliations
- Department of Internal Medicine III University Hospital of Ulm Ulm Germany.
- Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Germany.
- Department of Internal Medicine IV University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg Halle (Saale) Germany.
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hannover Germany.
- Department of Computational Oncology, Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York New York United States of America.
- Department of Hematology, Oncology and Cancer Immunology Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin Berlin Germany.
- German Cancer Consortium (DKTK) Partner Site Berlin Germany.
- National Center for Tumor Diseases (NCT) Partner Site Berlin Germany.
MeSH
Leukemia, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Mutation